Tag:
Lupin
Latest Headlines
Latest Headlines
No more working Saturdays at exports-minded Cipla
Why isn't Cipla as big as Ranbaxy Laboratories ? That's the central question of an Economic Times story profiling Chairman Yusuf Hamied and his company's recent changes. After years of promoting from
Lupin expands Japanese reach with I'Rom buy
India's Lupin has made a second foray into Japan , striking a deal to buy the Tokyo-based injectables maker I'Rom Pharmaceutical. The buyout follows Lupin's acquisition of Kyowa Pharmaceuticals, which
Takeda eyes Indian M&A, but Cipla, Lupin deny talks
Takeda Pharmaceutical is shopping in India, but whether it's buying is another story. Sources tell the Economic Times the Japanese drugmaker has been kicking tires over at Cipla and Lupin, both major
Medicis inks $58M dermatology pact with India's Lupin
The media blitz focused on Medicis CEO Jonah Shacknai in the wake of the bizarre death of his girlfriend hasn't prevented the company from completing new development pacts. While a U.S. subsidiary of
Lupin said to weigh sale of Indian pharma unit
Lupin's Indian drugs business may be on the block. Sources tell Bloomberg the company's founding shareholders, who together own 47% of the India-based company, are shopping the domestic drug
Lupin sets sights on birth control market
India's Lupin is eyeing a $200 million chunk of the U.S. contraceptive market. The company has asked FDA to approve 11 of its copycat oral contraceptives, and plans to file another 10 apps within
Lupin snags Antara rights for $38.6M
Back in January, Oscient Pharmaceuticals filed a patent infringement lawsuit against India's Lupin Pharmaceuticals ( LUPN ) over the cholesterol drug Antara (fenofibrate). Just days ago, Lupin
SPOTLIGHT: Indian pharmas woo Romania's LaborMed
Three Indian pharma companies--Shreya Lifesciences, Dr. Reddy's Laboratories, and Lupin--are in the race to buy Romania's LaborMed, which markets some 80 products in that country. The price is
ALSO NOTED: Strong euro hitting Merck KGaA's revenue; U.S. sales boost Lupin's Q3 profits;
> German pharma Merck KGaA says a strong euro will depress its year-end sales; it reported a 74.9 percent drop in third-quarter profits on a one-time charge from its acquisition of Serono.
SPOTLIGHT: India's Lupin buying Japanese generics maker
Apparently all of pharma is looking to Asia--even the Asians. India's Lupin paid $60 million for a 79 percent interest in the Japanese pharma Kyowa to establish a "beachhead in the second-largest
